Other content in this Stream
LMNL to present two scientific posters with new preclinical data for PBI-4050 and the treatment of pulmonary arterial hypertension (“PAH”) at the American Heart Association conference.
PBI-4547 is a novel, orally active immune-metabolic agent which displays antidiabetic, antihyperlipidemic, anti-inflammatory and anti-fibrotic activity as shown in multiple animal models.
Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th fibrosis at the 56th ERA/EDTA congress
Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.
The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.
Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).
Prometic has advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).
n the ongoing Phase 2 clinical trial in patients with Alström syndrome, PBI-4050 was shown to significantly reduce liver and cardiac fibrosis.
In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF).
Treatment with PBI-4050 for 12 weeks positively affected biomarkers known to have antifibrotic activity
Clinical programs streamlined to manage costs for balance of 2018 and continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions
Prometic received clearance by Health Canada to commence a placebo-controlled phase 2 clinical trial with PBI-4050 in patients with metabolic syndrome and type 2 diabetes.
Clinical activity measured in the heart, liver, kidney and fat tissue in patients treated with PBI-4050 over an average of 52 weeks
Clinical benefits in both heart and liver observed in patients treated with PBI-4050 over an average of 52 weeks of treatment
The meeting will feature presentations to discuss the current treatment landscape, as well as the unmet medical need for treating patients with IPF.
Lead drug candidates PBI-4050 and Ryplazim™ (plasminogen) continue to deliver consistent and positive clinical activity and tolerability data
PBI-4050’s anti-fibrotic mechanism of action demonstrated to occur via simultaneous stimulation of GPR40 and inhibition of GPR84
Prometic announces today the outcome of a successful clinical development Type C meeting with the US Food and Drug Administration for its orally active anti-fibrotic lead drug candidate, PBI-4050.
In a gold-standard animal model proven to emulate pulmonary fibrosis in humans, Prometic’s Plasminogen (Ryplazim™) performed favorably compared to recently- approved IPF drugs to treat this condition.